Jul 15 |
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
|
Jun 24 |
7 Biotech Stocks to Buy on the Dip: June 2024
|
Jun 13 |
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
|
Jun 12 |
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
Jun 7 |
Alnylam, Pliant among stocks yet to face Q2 catalysts: Wells Fargo
|
Jun 6 |
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
|
May 21 |
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
|
May 14 |
Pliant reports phase 2 data on idiopathic pulmonary fibrosis asset bexotegrast
|
May 14 |
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
|
May 8 |
Pliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)
|